NPY5RA 972
an NPY5 antagonist for treatment of obesity; structure in first source
Also Known As:
N-(9-isopropyl-4-methyl-9H-carbazol-3-yl)morpholine-4-carboxamide; NPY5RA-972; NPY5RA972
Networked: 2
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
1. | Beck-Sickinger, Annette G:
1 article
(02/2007)
|
2. | Gannan, Emma:
1 article
(02/2007)
|
3. | Morris, Margaret J:
1 article
(02/2007)
|
4. | O'Brien, Terence J:
1 article
(02/2007)
|
5. | Stroud, Leanne M:
1 article
(02/2007)
|
6. | Birtles, Susan:
1 article
(08/2002)
|
7. | Block, Michael H:
1 article
(08/2002)
|
8. | Boyer, Scott:
1 article
(08/2002)
|
9. | Carroll, Debbie:
1 article
(08/2002)
|
10. | Clarkson, Paul:
1 article
(08/2002)
|
Related Diseases
1. | Seizures (Absence Seizure)
02/01/2007
- " A dual in vivo approach was used: the cumulative duration of seizures was quantified in adult male GAERS in 90-min electroencephalogram recordings following intracerebroventricular (i.c.v.) injection of: (i) subtype-selective agonists of Y1 ([Leu31Pro34]NPY, 2.5 nmol), Y2 (Ac[Leu(28,31)]NPY24-36, 3 nmol), Y5 receptors [hPP1(-17),Ala31,Aib32]NPY, 4 nmol), NPY (3 nmol) or vehicle; and following (ii) i.c.v. injection of antagonists of Y1 (BIBP3226, 20 nmol), Y2 (BIIE0246, 20 nmol) and Y5 (NPY5RA972, 20 nmol) receptors or vehicle, followed by NPY (3 nmol). "
|
2. | Body Weight (Weight, Body)
|
|
Related Drugs and Biologics